19,317 results match your criteria Bone Marrow Transplantation Long-Term Effects


Clinico-radiologic features of pleuroparenchymal fibroelastosis in children.

Pediatr Radiol 2019 Apr 19. Epub 2019 Apr 19.

Department of Pediatric Radiology, Texas Children's Hospital, 6701 Fannin St., Houston, TX, 77030, USA.

Background: Pleuroparenchymal fibroelastosis (PPFE) may be underdiagnosed clinically and radiographically in children with a remote history of cancer, leading to a delay in care and unnecessary lung biopsies.

Objective: To describe the characteristic clinical and radiologic findings of PPFE in a cohort of children to facilitate recognition and noninvasive diagnosis.

Materials And Methods: Clinical presentation, history of chemotherapy or radiation therapy, lung or bone marrow transplantation, and lung function testing and outcome were retrospectively extracted from the electronic medical records of eight children treated at our institution's pulmonary medicine clinic with histopathology confirmation of PPFE from 2008 to 2018. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00247-019-04405-5
Publisher Site
http://dx.doi.org/10.1007/s00247-019-04405-5DOI Listing
April 2019
1 Read

[Children and adolescents discharge guidelines after allogeneic stem cell transplantation for healthcare professionals: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Bull Cancer 2019 Apr 15. Epub 2019 Apr 15.

Hôpital Robert-Debré, département d'hémato-immunologie pédiatrique, 48, boulevard Serurier, 75019 Paris, France; Université Paris 7-Paris Diderot, 5, rue Thomas-Mann, 75013 Paris, France. Electronic address:

Recommendations for visits or environment restrictions, and sometimes for food are usually well described for inpatient within HSCT unit procedures where those measures are less precise and detailed for outpatient from the discharge to the immune reconstitution achievement. The present paper main objective is to define risk patient groups depending on time, immune-suppressive drugs as well as graft-versus-host disease and immune reconstitution. We define here 3 risk patient groups and propose measures about house cleaning, pets, schools, social activities, hygiene, foods, sexual life and siblings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.03.006DOI Listing

Implementing safe and robust Total Marrow Irradiation using Helical Tomotherapy - A practical guide.

Phys Med 2019 Apr 6;60:162-167. Epub 2019 Apr 6.

Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.

Total Marrow Irradiation (TMI) with Helical Tomotherapy is a radiotherapy treatment technique that targets bone marrow and sanctuary sites prior to stem cell or bone marrow transplantation (SCT/BMT). TMI is a complex procedure that involves several critical steps that all need to be carefully addressed for a successful implementation, such as dose homogeneity in field junctions, choice of target margins, integrity of treatment and back-up planning. In this work we present our solution for a robust and reproducible workflow throughout the treatment chain and data for twenty-three patients treated to date. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmp.2019.03.032DOI Listing

A New Face Subunit Transplant Model in Mice, Containing Skin, Mandible, and Oral Mucosa for Future Face Vascularized Composite Allotransplantation Studies.

Plast Reconstr Surg 2019 Apr 11. Epub 2019 Apr 11.

Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Background: In immunologic research, mice have advantages over other animals, such as low costs, easy handling, suitable lifecycle, and adequate laboratory resources. However, mice vascularized composite allotransplantation (VCA) surgery is not popular, partly because of technical difficulties and high mortality rates. Our goal was to demonstrate a face transplantation model in mice that includes skin, mandible and oral mucosa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PRS.0000000000005774DOI Listing

Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.

Lancet Haematol 2019 Apr 10. Epub 2019 Apr 10.

San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy; Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electronic address:

Background: Wiskott-Aldrich syndrome is a rare, life-threatening, X-linked primary immunodeficiency characterised by microthrombocytopenia, infections, eczema, autoimmunity, and malignant disease. Lentiviral vector-mediated haemopoietic stem/progenitor cell (HSPC) gene therapy is a potentially curative treatment that represents an alternative to allogeneic HSPC transplantation. Here, we report safety and efficacy data from an interim analysis of patients with severe Wiskott-Aldrich syndrome who received lentiviral vector-derived gene therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30021-3DOI Listing
April 2019
1 Read

In vivo transplantation of stem cells with a genipin linked scaffold for tracheal construction.

J Biomater Appl 2019 Apr 10:885328219839193. Epub 2019 Apr 10.

1 Department of Cardiothoracic Surgery, Clinical medical college of Yangzhou University, Yangzhou, China.

To establish the procedures of genipin-linked scaffold for in situ tracheal reconstruction in a rabbit model, and to demonstrate whether stem cells can be further differentiated in the bioreactor in vivo. It will further provide an experimental and theoretical foundation for clinical application. Previously, in vitro evaluation proved the detergent-enzymatic method effectively removed stromal epithelial cells, and the number of nuclei was reduced significantly ( p < 0. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0885328219839193
Publisher Site
http://dx.doi.org/10.1177/0885328219839193DOI Listing
April 2019
3 Reads

Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia.

Int J Hematol 2019 Apr 8. Epub 2019 Apr 8.

Division of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan.

Outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) for hepatitis-associated aplastic anemia have not been fully evaluated. In the present study, the outcomes of 37 adult patients with hepatitis-associated aplastic anemia who underwent allogeneic HSCT were retrospectively analyzed using the registry database of Japan Society for Hematopoietic Cell Transplantation. The median age of the patients was 24 years (range, 16-61). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02644-8DOI Listing
April 2019
1 Read

Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.

Bone Marrow Transplant 2019 Apr 8. Epub 2019 Apr 8.

Department of Medical Sciences, Division of Hematology, Uppsala University Hospital, Uppsala, Sweden.

Two decades after the introduction of tyrosine kinase inhibitors (TKI), a sizeable portion of patients with chronic myeloid leukemia (CML) in chronic phase (CP) still undergo allogeneic stem cell transplantation (allo-HSCT). We investigated the indications for allo-HSCT, clinical outcome, management of relapse, and post-transplant TKI treatment in a population-based setting using the Swedish CML registry. Of 118 CML patients transplanted between 2002 and 2017, 56 (47. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0513-5DOI Listing
April 2019
1 Read

Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis.

Bone Marrow Transplant 2019 Apr 8. Epub 2019 Apr 8.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Ruxolitinib (Rux), a Jak1/2 inhibitor, results in reduced spleen size and improvement in constitutional symptoms in the majority of patients with myelofibrosis (MF). Therefore Rux, when given prior to hematopoietic cell transplantation (HCT) in patients with MF was hypothesized to improve engraftment, decrease incidence and severity of graft-versus-host disease, and lower non-relapse mortality (NRM). We conducted a phase II prospective trial to assess the effects of pre-HCT Rux on post-HCT outcomes in patients with MF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0523-3DOI Listing
April 2019
1 Read

Osteomyelitis Caused by Carbapenemase-Producing Klebsiella Pneumoniae: A Diagnosis to Consider in Patients with Hematologic Malignancies and Stem Cell Transplant Recipients.

Am J Case Rep 2019 Apr 9;20:482-488. Epub 2019 Apr 9.

Department of Hematology and Bone Marrow Transplantation, Hospital de Santa Maria, CHLN - EPE, Lisboa, Portugal.

BACKGROUND Osteomyelitis (OM) due to carbapenemase-producing Klebsiella pneumoniae (CPKp) is a very rare but severe condition, particularly among patients with hematologic malignancies and stem cell transplant recipients, who are especially at risk of developing nosocomial infections caused by this bacterium. CASE REPORT We describe 2 cases of acute and chronic OM by CPKp in adults with hematologic disorders. Patient 1, with acute lymphoblastic leukemia, developed bacteremia due to multidrug CPKp after induction chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.909965DOI Listing
April 2019
1 Read

Outcome and prognostic factors of children with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib followed by allogeneic hematopoietic cell transplantation in first remission.

Blood Res 2019 Mar 21;54(1):45-51. Epub 2019 Mar 21.

Department of Pediatrics, The Catholic University of Korea, Seoul, Korea.

Background: Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is a subset of ALL with poor prognosis. Here, we analyzed the outcomes and prognostic factors of children with Ph+ ALL who received imatinib and chemotherapy followed by allogeneic hematopoietic cell transplantation (HCT) in first complete remission (CR).

Methods: Thirty-one Ph+ ALL patients (female 10) diagnosed from January 2005 to December 2016 were included in the study. Read More

View Article

Download full-text PDF

Source
https://synapse.koreamed.org/DOIx.php?id=10.5045/br.2019.54.
Publisher Site
http://dx.doi.org/10.5045/br.2019.54.1.45DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439289PMC
March 2019
5 Reads

Effect of Chitosan Nanoparticle-Loaded on Hydrogen Peroxide-Induced Bone Marrow Stromal Cell Damage.

Stem Cells Int 2019 26;2019:5142518. Epub 2019 Feb 26.

Tissue Engineering Group (TEG), National Orthopaedic Centre of Excellence in Research and Learning (NOCERAL), Department of Orthopaedic Surgery, Faculty of Medicine, University of Malaya, Lembah Pantai, 50603 Kuala Lumpur, Malaysia.

We have determined the protective effects of (TS) extract and nanoparticle-loaded TS on hydrogen peroxide-induced cell death of mesenchymal stromal cells (MSCs) . Gas chromatography-mass spectroscopy confirmed the spectrum of active components in the extract. Out of the three different extracts, the hexane extract showed significant free radical scavenging activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/5142518DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431441PMC
February 2019

Strong expression of p53 protein in bone marrow samples after hematopoietic stem cell transplantation indicates risk of relapse in pediatric acute lymphoblastic leukemia patients.

Pediatr Transplant 2019 Apr 6:e13408. Epub 2019 Apr 6.

Department of Clinical Science, Intervention and Technology, Karolinska Institutet, CLINTEC, Stockholm, Sweden.

Background: For pediatric ALL patients that relapse or respond poorly to conventional chemotherapy treatment, HSCT is one treatment option. Still, relapse occurs in 30% of the children after HSCT. Mutations in the tumor suppressor gene TP53 which can lead to an altered p53 protein expression are rare at time of diagnosis of ALL, yet occur more frequent at relapse indicating a more aggressive disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/petr.13408DOI Listing
April 2019
1 Read

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.

Cancer Med 2019 Apr 4. Epub 2019 Apr 4.

Unit of Blood Diseases and Stem Cell Transplantation, DPT of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.

Treatment-free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation in patients with deep molecular response (DMR) is a paramount goal in the current chronic myeloid leukemia (CML) therapeutic strategy. The best DMR level by real-time quantitative PCR (RT-qPCR) for TKI discontinuation is still a matter of debate. To compare the accuracy of digital PCR (dPCR) and RT-qPCR for BCR-ABL1 transcript levels detection, 142 CML patients were monitored for a median time of 24 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2087DOI Listing
April 2019
2 Reads

Clinical Metabolomics Identifies Blood Serum Branched Chain Amino Acids as Potential Predictive Biomarkers for Chronic Graft vs. Host Disease.

Front Oncol 2019 18;9:141. Epub 2019 Mar 18.

Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas, Brazil.

The allogeneic hematopoietic stem cell transplantation procedure-the only curative therapy for many types of hematological cancers-is increasing, and graft vs. host disease (GVHD) is the main cause of morbidity and mortality after transplantation. Currently, GVHD diagnosis is clinically performed. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fonc.2019.00141/
Publisher Site
http://dx.doi.org/10.3389/fonc.2019.00141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436081PMC
March 2019
4 Reads

Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study.

Haematologica 2019 Apr 4. Epub 2019 Apr 4.

Dana Farber/Boston Children's Cancer and Blood Disorders Center, Boston MA

Quality of response to immunosuppressive therapy and long-term outcomes for pediatric severe aplastic anemia remain incompletely characterized. Contemporary evidence to inform treatment of relapsed or refractory severe aplastic anemia are also limited for pediatric patients. The clinical features and outcomes for 314 children treated from 2002-2014 with immunosuppressive therapy for acquired severe aplastic anemia were analyzed retrospectively from 25 institutions in the North American Pediatric Aplastic Anemia Consortium. Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.206540DOI Listing
April 2019
12 Reads

Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.

Leuk Lymphoma 2019 Apr 3:1-8. Epub 2019 Apr 3.

a Department of Hematology and Bone Marrow Transplantation , Rambam Health Care Campus , Haifa , Israel.

Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk AML patients. Sixty-six patients were included: 32 had mutated NPM1/wild-type FLT-ITD, 16 had t(8:21) and 18 - inv(16). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1594214DOI Listing
April 2019
2 Reads

Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS.

Blood 2019 Apr 1. Epub 2019 Apr 1.

Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan;

This study was performed to assess the utility of tumor-derived fragmentary DNA, or circulating tumor DNA (ctDNA), for identifying high-risk patients for relapse of acute myeloid leukemia and myelodysplastic syndrome (AML/MDS) after undergoing myeloablative allogeneic stem cell transplantation (alloSCT). We retrospectively collected tumor and available matched serum samples at diagnosis and 1 and 3 months post-alloSCT from 53 patients with AML/MDS. After identifying driver mutations in 51 patients using next-generation sequencing, we designed at least one personalized digital-PCR assay per case. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-10-880690DOI Listing
April 2019
4 Reads

Airway Management in Patients with Mucopolysaccharidoses: The Progression Towards Difficult Intubation.

Paediatr Anaesth 2019 Mar 31. Epub 2019 Mar 31.

Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, USA.

Background: Patients with mucopolysaccharidoses have physical changes to their airways over time. Due to the natural progression of their disease, these patients become more difficult to intubate as they get older.

Aims: The aims of this study were to evaluate the difficulty of airway management in mucopolysaccharidoses patients over time, and to evaluate the effect of bone marrow transplant and/or enzyme replacement therapy on airway difficulty. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/pan.13640
Publisher Site
http://dx.doi.org/10.1111/pan.13640DOI Listing
March 2019
3 Reads

Clinical Features and HSCT Outcome for SCID in Turkey.

J Clin Immunol 2019 Mar 28. Epub 2019 Mar 28.

Department of Pediatric Immunology, Hacettepe University Medical School, Ankara, Turkey.

Severe combined immunodeficiency (SCID) is the most serious PID, characterized by T cell lymphopenia and lack of antigen-specific T cell and B cell immune responses, inevitably leading to death within the first year of life if hematopoietic stem cell transplantation (HSCT) is not performed.

Purpose And Methods: Since SCID is a common type of PID with an estimated incidence of 1/10.000 in Turkey, a retrospective analysis of HSCT characteristics, survival, immune recovery, and the major clinical features of SCID prior to HSCT is the aim of this multi-transplant center-based analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10875-019-00610-xDOI Listing
March 2019
1 Read

Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience.

Ann Hematol 2019 Mar 27. Epub 2019 Mar 27.

School of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski street 25, 40-032, Katowice, Poland.

In the pathway inhibitor era, the number of allogeneic stem cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL) continues to decrease and this approach should be offered only after careful risk-benefit assessment. Nevertheless, ASCT still remains only curative therapeutic modality for CLL, especially in countries with limited access to novel agents. Thirty patients with CLL at median age of 42 years at diagnosis (range 29-64) underwent ASCT between years 2002 and 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03679-xDOI Listing
March 2019
1 Read

The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study.

Ann Hematol 2019 Mar 27. Epub 2019 Mar 27.

Clinical Center Nursing Department, National Institutes of Health, Bethesda, MD, USA.

The microbiome, an intriguing component of the human body, composed of trillions of microorganisms, has prompted scientific exploration to identify and understand its function and role in health and disease. As associations between microbiome composition, disease, and symptoms accumulate, the future of medicine hinges upon a comprehensive knowledge of these microorganisms for patient care. The oral microbiome may provide valuable and efficient insight for predicting future changes in disease status, infection, or treatment course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03599-wDOI Listing
March 2019
3 Reads

Long-Term Outcomes of BMMSC Compared with BMMNC for Treatment of Critical Limb Ischemia and Foot Ulcer in Patients with Diabetes.

Cell Transplant 2019 Mar 27:963689719835177. Epub 2019 Mar 27.

1 Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China.

Background:: We first compared long-term clinical outcomes in treating critical limb ischemia (CLI) and foot ulcer in patients with diabetes between autologous bone marrow mesenchymal stem cell (BMMSC) and bone-marrow-derived mononuclear cell (BMMNC) transplants. Methods: Forty-one patients were enrolled and followed up for 3 years. They received an 18-day standard treatment before stem cell transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0963689719835177DOI Listing
March 2019
1 Read
3.570 Impact Factor

The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas.

Am J Hematol 2019 Mar 27. Epub 2019 Mar 27.

Division Hematology, Oncology, and Bone Marrow Transplantation, University of Iowa, Iowa City, Iowa.

Indolent B-cell lymphomas other than follicular lymphoma account for up to 10% of all B-cell neoplasms. While they typically follow a slowly progressive course, some patients experience rapid progression and early mortality. Prognostic scoring systems have not been adopted, hindering the ability of clinicians or researchers to predict outcomes, or risk-stratify patients during clinical trials. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25473
Publisher Site
http://dx.doi.org/10.1002/ajh.25473DOI Listing
March 2019
2 Reads

A Pilot Study of Human Milk to Reduce Intestinal Inflammation After Bone Marrow Transplant.

Breastfeed Med 2019 Apr 27;14(3):193-202. Epub 2019 Mar 27.

1 Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Objective: Human milk administration in the early peritransplant period would lower intestinal inflammation after bone marrow transplant (BMT).

Materials And Methods: Children 0-5 years undergoing BMT received either a ready-to-feed human milk preparation designed for these children (Prolacta Bioscience, Duarte, CA) or standard formula. Babies breastfeeding at the time of BMT were also enrolled on the human milk arm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/bfm.2018.0199DOI Listing
April 2019
2 Reads

A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.

PLoS One 2019 26;14(3):e0212837. Epub 2019 Mar 26.

Merck & Co., Inc., Merck Research Laboratories, Kenilworth, NJ, United States of America.

Background: Posaconazole (POS) is a potent triazole antifungal agent approved in adults for treatment and prophylaxis of invasive fungal infections (IFIs). The objectives of this study were to evaluate the pharmacokinetics (PK), safety, and tolerability of POS oral suspension in pediatric subjects with neutropenia.

Methods: This was a prospective, multicenter, sequential dose-escalation study. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212837PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435162PMC
March 2019
3 Reads
3.234 Impact Factor

Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.

J Clin Invest 2019 Mar 26;130. Epub 2019 Mar 26.

Post-transplantation cyclophosphamide (PTCy) recently has had a marked impact on human allogeneic hematopoietic cell transplantation (HCT). Yet, our understanding of how PTCy prevents graft-versus-host disease (GVHD) largely has been extrapolated from major histocompatibility complex (MHC)-matched murine skin allografting models that were highly contextual in their efficacy. Herein, we developed a T-cell-replete, MHC-haploidentical, murine HCT model (B6C3F1→B6D2F1) to test the putative underlying mechanisms: alloreactive T-cell elimination, alloreactive T-cell intrathymic clonal deletion, and suppressor T-cell induction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI124218DOI Listing
March 2019
4 Reads

Outcomes of paroxysmal nocturnal hemoglobinuria in the pediatric age group in a resource-constrained setting.

Pediatr Blood Cancer 2019 Mar 26:e27712. Epub 2019 Mar 26.

Department of Hematology, All India Institute of Medical Sciences, New Delhi, India.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal stem cell disorder. Eculizumab and bone marrow transplantation are disease-modifying treatments for PNH but may not be readily available in resource-constrained settings. Of 52 pediatric patients with PNH, 20 had classical PNH and 32 had PNH/aplastic anemia (PNH/AA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27712DOI Listing
March 2019
1 Read

A double-virally-inactivated (Intercept-solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells.

Transfusion 2019 Mar 25. Epub 2019 Mar 25.

International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.

Background: Pooled human platelet lysate (HPL) can replace fetal bovine serum (FBS) as xeno-free supplement for ex vivo expansion of mesenchymal stromal cells (MSCs). We evaluate here whether a double-virally-inactivated HPL (DVI-HPL) prepared from expired Intercept-treated platelet concentrates (PCs) and treated by solvent/detergent (S/D) can be used for MSC expansion.

Study Design And Methods: Expired Intercept-treated PCs in 65% platelet (PLT) additive solution were pooled and subjected to a 1% tri-n-butyl phosphate/1% Triton X-45 treatment followed by soybean oil, hydrophobic interaction chromatography purification, and sterile filtration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15251DOI Listing
March 2019
1 Read

Organ donation - "attitude and awareness among undergraduates and postgraduates of North-East India".

J Family Med Prim Care 2019 Jan;8(1):130-136

Department of Anatomy, NEIGRIHMS, Shillong, Meghalaya, India.

Background: Organ donation is defined as "When a person allows an organ of theirs to be removed, legally, either by consent while the donor is alive or after death with the assent of the next of the kin." Common transplantations after organ donations include kidney, heart, liver, pancreas, intestines, lungs, bones, bone marrow, skin, and cornea. Although some organs such as kidney and tissues like part of the liver, pancreas, lungs, and intestines can be donated while the donor is alive, most of the donations occur only after the donor's death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jfmpc.jfmpc_206_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396593PMC
January 2019
4 Reads

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation.

Nat Med 2019 Apr 25;25(4):603-611. Epub 2019 Mar 25.

Unit of Immunogenetics, Leukemia Genomics and Immunobiology, Division of Immunology, Transplantation and Infectious Disease, IRCCS San Raffaele Scientific Institute, Milano, Italy.

Transplantation of hematopoietic cells from a healthy individual (allogeneic hematopoietic cell transplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood cancers: still, post-transplantation relapses remain frequent. To explain their drivers, we analyzed the genomic and gene expression profiles of acute myeloid leukemia (AML) blasts purified from patients at serial time-points during their disease history. We identified a transcriptional signature specific for post-transplantation relapses and highly enriched in immune-related processes, including T cell costimulation and antigen presentation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-019-0400-zDOI Listing
April 2019
3 Reads

Defining Moments: Making Time for Virtual Visits and Catalyzing Better Cancer Care.

Health Commun 2019 Mar 24:1-5. Epub 2019 Mar 24.

a Pediatric Hematology/Oncology and Bone Marrow Transplantation , Pediatrics Institute and Taussig Cancer Institute.

Time is quite possibly a physician's most valuable asset, yet the tendency of almost all physicians is to be overly committed. How do we slowdown and make a meaningful difference? Virtual visits provide a new way to share and care without sacrificing the important nuances of face-to-face communication. When the Cleveland Clinic expanded our Distance Health capabilities in 2017 using virtual visits, we began a successful journey which provides cancer patients and their caregivers a new type of expert, unrushed cancer care access. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10410236.2019.1
Publisher Site
http://dx.doi.org/10.1080/10410236.2019.1587695DOI Listing
March 2019
2 Reads

The role of specialized hospital units in infection and mortality risk reduction among patients with hematological cancers.

PLoS One 2019 20;14(3):e0211694. Epub 2019 Mar 20.

Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.

Motivation: Patients with hematological malignancies are susceptible to life-threatening infections after chemotherapy. The current study aimed to evaluate whether management of such patients in dedicated inpatient and emergency wards could provide superior infection prevention and outcome.

Methods: We have developed an approach allowing to retrieve infection-related information from unstructured electronic medical records of a tertiary center. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211694PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426175PMC
March 2019
6 Reads

Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients.

Bone Marrow Transplant 2019 Mar 19. Epub 2019 Mar 19.

Hematology Department, Institut Paoli Calmettes, Marseille, France.

While bone marrow (BM) grafts were initially used for T-replete HLA-haploidentical related donors transplantation (Haplo-SCT) with post-transplantation cyclophosphamide (PT-Cy), the use of peripheral blood stem cell (PBSC) remains debated. We thus conducted a detailed analysis evaluating the incidence, risk factors, and prevalence of GVHD after PBSC Haplo-SCT with PT-Cy. One hundred and eighty-one patients with hematological diseases were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0500-xDOI Listing
March 2019
1 Read

Amniotic fluid, an effective factor for umbilical cord blood hematopoietic stem cells in cell culture: An approach for bone marrow transplantation.

Transfus Apher Sci 2019 Jan 25. Epub 2019 Jan 25.

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Electronic address:

Bone marrow transplantation is a treatment used for hematologic and non-hematologic disorders. A theory suggests that proliferation of cells in non-body condition helps to increase the efficiency of bone marrow transplant. There are different ways for proliferation of stem cells, in which, most studies have focused on stem cell culture in body-like conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transci.2019.01.001DOI Listing
January 2019
2 Reads

Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years.

Blood Adv 2019 Mar;3(6):862-868

Department of Pediatrics and Adolescent Medicine.

Osteopetrosis (OP) is a rare disease caused by defective osteoclast differentiation or function. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment available in the infantile "malignant" form of OP. Improved clinical and genetic diagnosis of OP has seen the emergence of a cohort of patients with less severe and heterogeneous clinical presentations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018025890DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436016PMC
March 2019
2 Reads

Human iPSC-derived MSCs (iMSCs) from aged individuals acquire a rejuvenation signature.

Stem Cell Res Ther 2019 Mar 18;10(1):100. Epub 2019 Mar 18.

Institute for Stem Cell Research and Regenerative Medicine, Medical Faculty, Heinrich Heine University, Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.

Background: Primary mesenchymal stem cells (MSCs) are fraught with aging-related shortfalls. Human-induced pluripotent stem cell (iPSC)-derived MSCs (iMSCs) have been shown to be a useful clinically relevant source of MSCs that circumvent these aging-associated drawbacks. To date, the extent of the retention of aging-hallmarks in iMSCs differentiated from iPSCs derived from elderly donors remains unclear. Read More

View Article

Download full-text PDF

Source
https://stemcellres.biomedcentral.com/articles/10.1186/s1328
Publisher Site
http://dx.doi.org/10.1186/s13287-019-1209-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423778PMC
March 2019
9 Reads
3.368 Impact Factor

Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant.

JAMA Pediatr 2019 Mar 18:e190081. Epub 2019 Mar 18.

Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Importance: Studies demonstrating improved survival after allogeneic hematopoietic cell transplant generally exclude infants.

Objective: To analyze overall survival trends and other outcomes among infants who undergo allogeneic hematopoietic cell transplant.

Design, Setting, And Participants: In this cohort study, we used time-trend analysis to evaluate 3 periods: 2000 through 2004, 2005 through 2009, and 2010 through 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamapediatrics.2019.0081DOI Listing
March 2019
2 Reads

Abdominal Aortic Transplantation of Bone Marrow Mesenchymal Stem Cells Regulates the Expression of Ciliary Neurotrophic Factor and Inflammatory Cytokines in a Rat Model of Spinal Cord Ischemia-Reperfusion Injury.

Med Sci Monit 2019 Mar 15;25:1960-1969. Epub 2019 Mar 15.

Department of Anesthesiology, The First Peoples' Hospital of Yunnan Province, Kunming, Yunnan, China (mainland).

BACKGROUND This study aimed to investigate the effects of abdominal aortic transplantation of bone marrow mesenchymal stem cells (BMMSCs) on the expression of inflammatory cytokines in a rat model of spinal cord ischemia-reperfusion injury. MATERIAL AND METHODS Adult female Sprague-Dawley rats (N=160) were divided into five groups: the sham operation group (N-32); the control group (N=32); the BMMSC transplanted group (N=32); the anti-ciliary neurotrophic factor (CNTF)-treated BMMSC transplanted group (N=32); and the CNTF small interfering RNA (siRNA)-treated BMMSC transplanted group (N=32). Motor behavior was assessed using the Basso, Beattie, and Bresnahan (BBB) locomotor scale. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.912697DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434608PMC
March 2019
1 Read

Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Mar 11. Epub 2019 Mar 11.

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France; INSERM, UMR 938, Paris, France; Sorbonne Universités, Université Pierre et Marie Curie Paris 6, Paris, France. Electronic address:

We report the outcomes of 51 patients who underwent unmanipulated haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide (PT-Cy) and antithymocyte globulin (ATG), from peripheral blood stem cells (PBSCs) or bone marrow, after receipt of a TBF (thiotepa, busulfan, and fludarabine) conditioning regimen. Their median age was 55 years (range, 16 to 72 years). Hematologic diagnoses included acute leukemias (n = 31), lymphoid neoplasm (n = 12), myeloproliferative neoplasm (n = 5), and myelodysplastic syndromes (n = 3). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.025DOI Listing
March 2019
6 Reads

Efficacy of bone marrow mesenchymal stem cell transplantation in animal models of pulmonary fibrosis after exposure to bleomycin: A meta-analysis.

Exp Ther Med 2019 Mar 28;17(3):2247-2255. Epub 2019 Jan 28.

Department of Toxicology, Shandong Academy of Occupational Health and Occupational Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China.

Previous studies have demonstrated that bone marrow mesenchymal stem cell (BMSC) transplantation is a promising treatment strategy for pulmonary fibrosis. Although encouraging results have been obtained using animal models of bleomycin (BLM)-induced pulmonary fibrosis, it is evident that transplantation of BMSCs at various time-points after BLM administration has produced different results in terms of treatment efficacy. To shed light on the potential utility of BMSCs for the treatment of lung disease, the present study performed a meta-analysis to estimate the efficacy of BMSCs in animal models of BLM-induced pulmonary fibrosis, and compare early transplantation (BMSCs injected on the same day after administration of BLM) with late transplantation (BMSCs injected on the 14th day after administration of BLM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2019.7205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395999PMC

ABO blood type incompatibility lost the unfavorable impact on outcome in unrelated bone marrow transplantation.

Bone Marrow Transplant 2019 Mar 13. Epub 2019 Mar 13.

Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

The effects of ABO incompatibility on hematopoietic stem cell transplantation remain controversial. Large cohorts are required to obtain findings that allow for definite conclusions. We previously demonstrated poor overall survival and increased treatment-related mortality (TRM) in ABO-incompatible unrelated bone marrow transplantation (UR-BMT) performed during the period from 1993 to 2005. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-019-0496-2
Publisher Site
http://dx.doi.org/10.1038/s41409-019-0496-2DOI Listing
March 2019
4 Reads

Serial Cerebral Metabolic Changes in Patients With Ischemic Stroke Treated With Autologous Bone Marrow Derived Mononuclear Cells.

Front Neurol 2019 25;10:141. Epub 2019 Feb 25.

Institute for Stroke and Cerebrovascular Diseases, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.

Cell-based therapy offers new opportunities for the development of novel treatments to promote tissue repair, functional restoration, and cerebral metabolic balance. N-acetylasperate (NAA), Choline (Cho), and Creatine (Cr) are three major metabolites seen on proton magnetic resonance spectroscopy (MRS) that play a vital role in balancing the biochemical processes and are suggested as markers of recovery. In this preliminary study, we serially monitored changes in these metabolites in ischemic stroke patients who were treated with autologous bone marrow-derived mononuclear cells (MNCs) using non-invasive MRS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2019.00141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397870PMC
February 2019
3 Reads

In vitro expansion affects the response of human bone marrow stromal cells to irradiation.

Stem Cell Res Ther 2019 Mar 8;10(1):82. Epub 2019 Mar 8.

Department of Blood Transfusion, Irradiation biology laboratory, The Second Affiliated Hospital, Army Medical University, Xinqiao Road, Shapingba, Chongqing, 400037, China.

Background: Bone marrow stromal cells (BMSCs) are extensively used in regeneration therapy and cytology experiments simulate how BMSCs respond to radiation. Due to the small number and the heterogeneity of primary isolated BMSCs, extensive in vitro expansion is usually required before application, which affects the cellular characteristics and gene expression of BMSCs. However, whether the radiation response of BMSCs changes during in vitro expansion is unclear. Read More

View Article

Download full-text PDF

Source
https://stemcellres.biomedcentral.com/articles/10.1186/s1328
Publisher Site
http://dx.doi.org/10.1186/s13287-019-1191-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408817PMC
March 2019
4 Reads
3.368 Impact Factor

The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance.

Cell Stem Cell 2019 Mar;24(3):405-418.e7

Laboratory of Regenerative Hematopoiesis, Swiss Institute for Experimental Cancer Research (ISREC) & Institute of Bioengineering (IBI), School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland; Service and Central Laboratory of Hematology, Departments of Oncology and of Laboratories, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address:

It has been recently shown that increased oxidative phosphorylation, as reflected by increased mitochondrial activity, together with impairment of the mitochondrial stress response, can severely compromise hematopoietic stem cell (HSC) regeneration. Here we show that the NAD-boosting agent nicotinamide riboside (NR) reduces mitochondrial activity within HSCs through increased mitochondrial clearance, leading to increased asymmetric HSC divisions. NR dietary supplementation results in a significantly enlarged pool of progenitors, without concurrent HSC exhaustion, improves survival by 80%, and accelerates blood recovery after murine lethal irradiation and limiting-HSC transplantation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19345909193006
Publisher Site
http://dx.doi.org/10.1016/j.stem.2019.02.012DOI Listing
March 2019
7 Reads

Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?

Authors:
Dilan A Patel

World J Oncol 2019 Feb 26;10(1):1-9. Epub 2019 Feb 26.

Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, 2220 Pierce Avenue, Nashville, TN 37232, USA. Email:

Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide (PTCy) offers universal donor availability and can potentially cure relapsed or primary refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). However, a conditioning regimen intensity that balances the graft-versus-lymphoma (GvL) effect with regimen-related toxicities (RRTs) has not yet been optimized. Limited data exist on the management of relapse, which is common post-transplant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14740/wjon1164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396776PMC
February 2019
2 Reads

The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation.

Bone Marrow Transplant 2019 Mar 4. Epub 2019 Mar 4.

Acute Leukemia Working Party of the EBMT, Hopital Saint-Antoine, Paris, France.

The number of HLA-haploidentical hematopoietic cell transplants continues to increase worldwide due to recent improvements in outcomes, allowing more patients with hematological malignancies and non-malignant disorders to benefit from this procedure and have a chance to cure their disease. Despite these encouraging results, questions remain as multiple donors are usually available for transplantation, and choosing the best HLA-haploidentical donor for transplantation remains a challenge. Several approaches to haploidentical transplantation have been developed over time and, based on the graft received, can be grouped as follows: T-cell depleted haploidentical transplants, either complete or partial, or with T-cell replete grafts, performed with post-transplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis, or G-CSF-primed bone marrow graft and enhanced GVHD prophylaxis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0499-zDOI Listing
March 2019
3 Reads

Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34 Selected Allogeneic Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2019 Mar 1. Epub 2019 Mar 1.

Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York.

Antithymocyte globulin (ATG) use mitigates the risk of graft rejection and graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT), but ATG overexposure in the setting of lymphopenia negatively affects immune recovery. We hypothesized that standard empiric weight-based dosing of ATG, used to prevent graft rejection in ex vivo CD34-selected allo-HCT, may lead to serious adverse consequences on outcomes in certain patients. We evaluated 304 patients undergoing myeloablative-conditioned ex vivo CD34-selected allo-HCT with HLA-matched donors for the treatment of hematologic malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.021DOI Listing
March 2019
3 Reads

Pegfilgrastim: More Cost Effective and Equally Efficacious Option as Compared to Filgrastim in Autologous Stem Cell Transplant.

Indian J Hematol Blood Transfus 2019 Jan 17;35(1):66-71. Epub 2018 May 17.

Bone Marrow Transplantation and Medical Oncology Department, Prince Aly Khan Hospital, Mumbai, India.

Use of growth factor after high-dose chemotherapy (HDC) and autologous peripheral blood stem cell (PBSC) support is current standard in reducing days of neutropenia. This retrospective study aims to compare the efficacy of two standard growth factors, pegfilgrastim (PEG) and filgrastim (FIL) after HDC. We collected data on 195 consecutive adult patients who received an autotransplant (myeloma, lymphoma and others) between January 2004 and December 2014 at two tertiary care centres. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-018-0966-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369085PMC
January 2019
3 Reads

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.

Lancet Haematol 2019 Apr 27;6(4):e204-e216. Epub 2019 Feb 27.

Childrens Cancer Group, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Tata Translational Cancer Research Centre, Tata Medical Center, New Town, Kolkata, India. Electronic address:

Background: The ALLR3 trial investigated outcomes of children with B-cell precursor acute lymphoblastic leukaemia who had late bone marrow relapses. We analysed long-term follow-up outcomes of these patients.

Methods: ALLR3 was an open-label randomised clinical trial that recruited children aged 1-18 years with B-cell precursor acute lymphoblastic leukaemia who had late bone marrow relapses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30003-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445853PMC
April 2019
2 Reads